Takeda seeks dual Crohn's, UC indications for vedolizumab in US
This article was originally published in Scrip
Executive Summary
With its submission to the FDA of its biologics license application (BLA) for vedolizumab in the dual indications of moderately to severely active Crohn's disease and ulcerative colitis (UC), Takeda is seeking to take a big bite out of the sales of rivals Janssen's Remicade (infliximab) and Abbvie's Humira (adalimumab), UCB's Cimzia (certolizumab) and Biogen's Tysabri (natalizumab).